M. Vastola

National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.

T. Choueiri, K. Hoffman, B. Mahal, 2017, International journal of radiation oncology, biology, physics.

Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.

T. Choueiri, B. Mahal, Q. Trinh, 2018, Urologic oncology.

Active Surveillance for Low-Risk Prostate Cancer in Black Patients.

A. D'Amico, T. Rebbeck, R. Dess, 2019, The New England journal of medicine.

Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.

K. Hoffman, B. Mahal, F. Feng, 2017, European urology focus.

Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy.

K. Hoffman, B. Mahal, F. Feng, 2017, Urologic oncology.

Receipt of definitive therapy in elderly patients with unfavorable‐risk prostate cancer

B. Mahal, P. Orio, K. Mouw, 2017, Cancer.

Pathologic Outcomes of Gleason 6 Favorable Intermediate‐Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance

B. Mahal, Q. Trinh, P. Orio, 2017, Clinical genitourinary cancer.

Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.

T. Choueiri, B. Mahal, P. Orio, 2020, Urologic oncology.